{
  "title": "180 Life Sciences: Looking At Inflammation With Cannabis",
  "author": "Seeking Alpha",
  "dc:creator": "Seeking Alpha",
  "enclosure": "",
  "guid": "c14fe0ca-10e0-11ec-a25c-033a9fcd9ae7",
  "pubDate": "Wed, 08 Sep 2021 20:01:00 GMT",
  "link": "https://the-cannabis-investing-podcast.sounder.fm",
  "description": "<p>180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded the company with cannabis trailblazer Prof. Raphael Mechoulam, joins Rena with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials. Limitations of bioavailability in CBD; non-psychoactive synthetic CBD.\nLearn more about your ad choices. Visit megaphone.fm/adchoices</p>",
  "content:encoded": "<p>180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded the company with cannabis trailblazer Prof. Raphael Mechoulam, joins Rena with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials. Limitations of bioavailability in CBD; non-psychoactive synthetic CBD.\nLearn more about your ad choices. Visit megaphone.fm/adchoices</p>",
  "itunes:title": "180 Life Sciences: Looking At Inflammation With Cannabis",
  "itunes:image": "",
  "itunes:author": "Seeking Alpha",
  "itunes:duration": "01:01:12",
  "itunes:explicit": false,
  "itunes:summary": "180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded the company with cannabis trailblazer Prof. Raphael Mechoulam, joins Rena with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials. Limitations of bioavailability in CBD; non-psychoactive synthetic CBD.\nLearn more about your ad choices. Visit megaphone.fm/adchoices",
  "itunes:episodeType": "full",
  "podcast:person": "Seeking Alpha",
  "podcast:transcript": "",
  "podcast:guid": "c14fe0ca-10e0-11ec-a25c-033a9fcd9ae7"
}